Drug intelligence / Profile preview

Afpin Cl

Development stage: Unknown
Lead developer: Zuventus Healthcare
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

**Afpin Cl** is an oral botanical joint-health product marketed by Zuventus for the treatment of mild-to-moderate osteoarthritis. Each vegetarian capsule contains *Curcuma longa* rhizome extract formulated as CurQlife and *Boswellia serrata* extract formulated as Aflapin. The product is intended to support reduction of osteoarthritis-associated inflammation, pain, stiffness, and impaired joint function; the *Boswellia serrata* extract is associated with inhibition of the 5-lipoxygenase inflammatory pathway. ([zuventus.com](https://www.zuventus.com/products/afpin-cl))

Brand names: Afpin Cl
Other names: AfpinAfpin-CL

Targets

ALOX5 (Arachidonate 5-lipoxygenase)COXTNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on Afpin Cl.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Afpin Cl.